This review focuses on genome-wide association studies (GWASs) of asthma and allergic
diseases published between January 1, 2018, and June 30, 2019. During this time period …

Identification of novel variants that contribute to response heterogeneity supports future
studies of single nucleotide polymorphism discovery and include gene expression and …

Background The primary rescue medication to treat acute asthma exacerbation is the short-
acting β 2-adrenergic receptor agonist; however, there is variation in how well a patient …

Background Inhaled capsaicin elicits cough reproducibly in human subjects and is widely
used in the study of cough and antitussive therapies. However, the traditional end points C2 …

Short-acting β2-adrenergic receptor agonists (SABAs) are the most commonly prescribed
asthma medications worldwide. Response to SABAs is measured as bronchodilator drug …

BACKGROUND: Despite the clinical improvements attributed to noninvasive ventilation
(NIV) during asthma crises, and the well established effects of nebulization, there are few …

Variability in response to short-acting β2-agonists (eg, albuterol) among patients with
asthma from diverse racial/ethnic groups may contribute to asthma disparities. We sought to …

C. Dinakar et al./Ann Allergy Asthma Immunol 113 (2014) 143e159 147 desired properties
(ie, ICS with formoterol) are available in the United States, the FDA has not approved those …

Background Bronchial thermoplasty (BT) has been shown to be effective in randomized
controlled trials of patients with severe asthma who failed to achieve disease control with …

Background and Aims GLCCI1 variations are found to be associated with response to
glucocorticoid therapy in non-Hispanic white subjects with asthma. However, there are also …